UNSPSC 51112023: Ruxolitinib

A type of kinase Inhibitor used to treat myelofibrosis.

UNSPSC 51112023 Ruxolitinib, a Commodity code, describes pharmaceuticals purchased directly by state health agencies for their medicaid and employee benefit programs. The Texas Health and Human Services Commission issued a Request for Information (RFI) in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment under its Therapeutic Pharmacy Initiative, signaling state-level interest in bypassing traditional pharmacy benefit managers and group purchasing organizations to manage pharmaceutical costs and improve fulfillment efficiency. State and local procurement under this code centers on agency acquisition of branded and generic medications for public health programs, employee health plans, and institutional formularies—a highly regulated, price-sensitive category where issuing bodies include state health departments, state employee benefits offices, county health authorities, and local public health districts. Ruxolitinib and similarly categorized pharmaceuticals are bought through formulary contracts, cooperative purchasing vehicles (such as state purchasing consortia), and direct manufacturer agreements negotiated by procurement offices managing self-insured health benefit populations.

Recent activity reflects Texas HHS as a repeat buyer conducting early-stage procurement strategy research rather than issuing a formal competitive solicitation. The April 2026 RFI sought vendor experience with direct contracting models, negotiated net pricing without rebates, and outcomes-based agreements—indicating the state is exploring alternatives to incumbent PBM and GPO channels before issuing a formal RFP. No award value, timeline, or geographic scope beyond Texas is provided in the current materials. The RFI's preliminary, information-gathering phase suggests that substantive competitive opportunities will follow only after the state completes vendor capability assessments and refines its procurement specifications and pricing framework. Firms pursuing this code should monitor Texas HHS for subsequent formal solicitations and track similar direct-to-manufacturer initiatives in other state health agencies and employee benefits offices.